Targeting MET in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The MET proto-oncogene encodes the c-MET receptor tyrosine kinase, crucial for hepatocyte growth factor (HGF) signaling.
• Activation of c-MET/HGF pathways regulates cell migration, proliferation, and angiogenesis, processes vital for development and implicated in cancer.
• MET exon 14 alterations and gene amplification are oncogenic drivers in various cancers.

Purpose of the Study:

• To review the role of MET alterations in cancer development.
• To summarize the clinical efficacy and safety of c-MET inhibitors across different cancer types.
• To highlight current and future therapeutic strategies targeting MET in oncology.

Main Methods:

• Literature review of preclinical and clinical studies on MET inhibitors.
• Analysis of clinical trial data for MET-targeted therapies in non-small cell lung cancer, gastrointestinal cancers, and hepatocellular carcinoma.
• Evaluation of the efficacy and safety profiles of specific MET inhibitors like cabozantinib and crizotinib.

Main Results:

• Cabozantinib and crizotinib demonstrated efficacy in advanced non-small cell lung cancer with manageable side effects.
• Phase III trials of MET inhibitors in gastrointestinal cancers have largely yielded negative results.
• Promising Phase II results in hepatocellular carcinoma have led to ongoing Phase III trials for MET inhibitors.

Conclusions:

• MET-targeted therapies, particularly c-MET inhibitors, offer a viable treatment strategy for specific cancers like non-small cell lung cancer.
• Further research and clinical trials are essential to optimize MET inhibitor efficacy and expand their application in other malignancies, including hepatocellular carcinoma.
• The therapeutic landscape for MET-driven cancers is evolving, necessitating continued investigation into targeted approaches.